New York, November 07, 2024 - PRISM MarketView - Cingulate Inc. (Nasdaq: CING) reported a $19.5 million increase in working capital in Q3 2024, strengthening its financial position to advance its lead ADHD asset, CTx-1301, toward a mid-2025 New Drug Application (NDA) submission. The company raised $12.5 million in capital during the quarter, extending its cash runway into Q3 2025. Additionally, Cingulate secured European patents for CTx-1301 in up to 30 territories, enhancing its global market potential and regained compliance with Nasdaq’s $1.00 minimum bid requirement.
R&D expenses decreased significantly to $1.4 million due to the completion of major clinical studies, contributing to a 46% reduction in net loss compared to Q3 2023. Total liabilities also decreased, reflecting a stronger balance sheet.
Cingulate’s CTx-1301 platform leverages its proprietary Precision Timed Release™ (PTR™) technology to address unmet needs in the ADHD market, which continues to see strong growth and demand for innovative treatment solutions. By targeting improved symptom management and patient adherence, CTx-1301 aims to capture meaningful market share.
Despite these positive developments, the company’s accumulated deficit reached $102.4 million, and its operating loss for Q3 2024 was $3.3 million. The company’s cash position of $10 million is expected to support operations through Q3 2025 but may require additional funding thereafter.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on X.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities